Quince Therapeutics, Inc.
QNCX
$1.22
-$0.04-3.18%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -15.15% | -9.61% | -28.82% | -3.66% | 64.20% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 60.61% | 32.97% | 11.91% | 49.13% | 73.01% |
| Operating Income | -60.61% | -32.97% | -11.91% | -49.13% | -73.01% |
| Income Before Tax | -191.64% | -146.18% | 42.29% | -34.76% | -40.80% |
| Income Tax Expenses | 44,842.86% | -453.85% | 86.11% | 51.61% | -86.27% |
| Earnings from Continuing Operations | -216.73% | -144.76% | 42.12% | -34.81% | -40.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -216.73% | -144.76% | 42.12% | -34.81% | -40.07% |
| EBIT | -60.61% | -32.97% | -11.91% | -49.13% | -73.01% |
| EBITDA | -60.48% | -33.90% | -12.07% | -49.45% | -82.22% |
| EPS Basic | -149.00% | -95.81% | 46.57% | -31.95% | -31.59% |
| Normalized Basic EPS | -154.33% | -12.79% | -74.07% | -50.86% | -112.49% |
| EPS Diluted | -149.00% | -95.81% | 46.57% | -31.95% | -31.59% |
| Normalized Diluted EPS | -154.33% | -12.79% | -74.07% | -50.86% | -112.49% |
| Average Basic Shares Outstanding | 27.20% | 24.99% | 8.33% | 2.16% | 6.45% |
| Average Diluted Shares Outstanding | 27.20% | 24.99% | 8.33% | 2.16% | 6.45% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |